Second Affiliated Hospital, Zhejiang University
浙江大学医学院附属第二医院
Listed for 33 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.
Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.
Official links opened and checked on 2026-11-08.
Research at Second Affiliated Hospital, Zhejiang University
Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.
Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed
- Nasopharyngeal carcinoma鼻咽癌1 paper led
- Oesophageal squamous cell carcinoma食管鳞状细胞癌4 papers led3 open trials led
- Hepatocellular carcinoma肝细胞癌68 papers led9 open trials led
- Stomach cancer胃癌58 papers led6 open trials led
- Retinoblastoma视网膜母细胞瘤1 paper led
- Chordoma脊索瘤0 papers led
- Osteosarcoma骨肉瘤16 papers led
- Gastrointestinal stromal tumour胃肠道间质瘤4 papers led
- Neuroblastoma神经母细胞瘤3 papers led
- Ewing sarcoma尤文肉瘤0 papers led
- Multiple myeloma多发性骨髓瘤5 papers led2 open trials led
- Haemophagocytic lymphohistiocytosis噬血细胞性淋巴组织细胞增生症2 papers led
- Thrombotic thrombocytopenic purpura血栓性血小板减少性紫癜1 paper led
- Neuromyelitis optica spectrum disorder视神经脊髓炎谱系疾病7 papers led
- Myasthenia gravis重症肌无力4 papers led
- Moyamoya disease烟雾病12 papers led
- Wilson disease肝豆状核变性(Wilson 病)8 papers led2 open trials led
- Anti-NMDA receptor encephalitis抗 NMDA 受体脑炎4 papers led
- Takayasu arteritis大动脉炎0 papers led
- Idiopathic pulmonary fibrosis特发性肺纤维化4 papers led
- Amyotrophic lateral sclerosis肌萎缩侧索硬化症6 papers led
- Fabry disease法布雷病0 papers led
- Pompe disease庞贝病0 papers led
- Duchenne muscular dystrophy杜氏肌营养不良1 paper led
- Behçet disease白塞病0 papers led
- Alport syndromeAlport 综合征1 paper led
- IgA nephropathyIgA 肾病2 papers led
- Osteogenesis imperfecta成骨不全症0 papers led
- Congenital diaphragmatic hernia先天性膈疝1 paper led
- Hirschsprung disease先天性巨结肠1 paper led
- Hereditary angioedema遗传性血管性水肿1 paper led
- Familial adenomatous polyposis家族性腺瘤性息肉病4 papers led
- Leber hereditary optic neuropathyLeber 遗传性视神经病变0 papers led
Not listed for: Hepatoblastoma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Fanconi anaemia, IgG4-related disease, Biliary atresia, Hepatic echinococcosis, Lymphangioleiomyomatosis, Spinal muscular atrophy, Gaucher disease, Niemann–Pick disease type C, Primary biliary cholangitis, Primary sclerosing cholangitis, Inherited epidermolysis bullosa, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.
Cancer
Nasopharyngeal carcinoma
鼻咽癌Led 1 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.04%.
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
8 hospitals in Hangzhou for nasopharyngeal carcinoma176 hospitals in China for nasopharyngeal carcinoma
No open trial on nasopharyngeal carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Papers it led1
All its trials on ClinicalTrials.gov, any status1
More papers found outside PubMed (not counted)4
- Camrelizumab plus taxanes and cisplatin (TP) chemotherapy or TP chemotherapy in patients with recurrent or metastatic nasopharyngeal carcinoma
- Additional file 1 of A two-stage genome-wide association study to identify novel genetic loci associated with acute radiotherapy toxicity in nasopharyngeal carcinoma
- Long intergenic non-protein coding RNA 02570 promotes nasopharyngeal carcinoma progression by adsorbing microRNA miR-4649-3p thereby upregulating both sterol regulatory element binding protein 1, and fatty acid synthase
- MA13.08 CHOICE-01: A Phase 3 Study of Toripalimab Versus Placebo in Combination With First-Line Chemotherapy for Advanced NSCLC
Cancer
Oesophageal squamous cell carcinoma
食管鳞状细胞癌Led 4 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.1%.
- Open trials as a site
- 0
- led by another institution
6 hospitals in Hangzhou for oesophageal squamous cell carcinoma191 hospitals in China for oesophageal squamous cell carcinoma
Open trials with this hospital 3
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingNeoadjuvant Ivonescimab(AK112) Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2026-06
- Registry
- NCT07244978
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingCamrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2026-08
- Registry
- NCT07505186
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingAdbelimumab Combined With Chemotherapy and Apatinib in Patients With Resectable Esophageal Squamous Cell Carcinoma
- Phase
- Phase 2
- Started
- 2024-08
- Registry
- NCT06576973
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led4
- Discovery of LD-110 as an Effective LSD1 PROTAC Degrader for the Treatment of Esophagus Squamous Cancer.
- Neoadjuvant serplulimab combined with chemotherapy for resectable oesophageal squamous cell carcinoma: a single-arm, phase 2 trial.
- Camrelizumab-induced oral lichenoid reaction with subepithelial CD4+ T-cell infiltration.
- Long Non-Coding RNA OIP5-AS1 Inhibits the Proliferation and Migration of Esophageal Squamous Carcinoma Cells by Targeting FOXD1/miR-30a-5p Axis and the Effect of Micro- and Nano-Particles on Targeting Transfection System.
All its trials on ClinicalTrials.gov, any status9
- Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma
- Neoadjuvant Ivonescimab(AK112) Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma
- Adbelimumab Combined With Chemotherapy and Apatinib in Patients With Resectable Esophageal Squamous Cell Carcinoma
- Cadonilimab/Anlotinib in Locally Advanced or Relapsed/Metastatic ESCC Patients After Failure of PD-1 Combined With Platinum-containing Chemotherapy
- Serplulimab Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma
- Carrelizumab, Chemotherapy and Apatinib in the Neoadjuvant Treatment of Resectable Esophageal Squamous Cell Carcinoma
- A Study of CS1001 in Subjects With Esophageal Squamous Cell Carcinoma
- Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension Study
- Nimotuzumab in Combined With Paclitaxel and Cisplatin for Treatment of Metastatic Esophageal Squamous Cell Carcinoma
More papers found outside PubMed (not counted)8
- 1319 First-in-human study of a personalized neoantigen peptide vaccine (iNeo-Vac-P01) for postoperative esophageal cancer in a Chinese cohort
- Abstract 2876: Spatial immune cell atlas predicts the sensitivity to neoadjuvant PD-1 blockade treatment combined with radiotherapy in resectable esophageal squamous cell carcinoma
- Clinical long-term oncologic outcomes of endoscopic noncurative resection for superficial esophageal squamous cell carcinoma: A single-center retrospective study
- Clinical pathological characteristics and expression of 328 proteins and their impact on survival in over 20,000 cases of esophageal squamous cell carcinoma and colorectal adenocarcinoma
- KC1036, a novel oral multi-kinase inhibitor, in patients with previously treated advanced esophageal squamous cell carcinoma (ESCC): Results from a multicenter, single-arm phase II trial.
- Abstract 6124: Interleukin-1β and exosomal M6PR secreted by serglycin-overexpressing esophageal cancer cells instigate fibroblasts and endothelial cells to promote esophageal cancer progression
- Additional file 1 of OTUB2 Regulates YAP1/TAZ to Promotes the Progression of Esophageal Squamous Cell Carcinoma
- Downregulation of long noncoding RNA breast cancer anti-estrogen resistance 4 inhibits cell proliferation, invasion, and migration in esophageal squamous cell carcinoma by regulating the microRNA-181c-5p/LIM and SH3 protein 1 axis
Cancer
Hepatocellular carcinoma
肝细胞癌Led 68 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.5%.
7 hospitals in Hangzhou for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma
Open trials with this hospital 13
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Prospective, Randomized Study of TACE Combined With Sintilimab, Bevacizumab, and Ipilimumab N01 Treating Advanced HCC
- Phase
- Phase 2
- Started
- 2026-03
- Registry
- NCT07422753
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingConstruction and Clinical Validation of a Predictive Model for Postoperative Adjuvant Therapy in Hepatocellular Carcinoma Based on Whole-Slide Digital Pathological Images and Deep Learning
- Phase
- Not given
- Started
- 2025-11
- Registry
- NCT07417800
Age 18 years to Not stated (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingStudy on the Classification of Comprehensive Treatment Effect of Hepatocellular Carcinoma
- Phase
- N/A
- Started
- 2024-09
- Registry
- NCT06542796
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingEarly-stage Detection of Liver Cancer by Proteins in Peripheral Blood
- Phase
- Not given
- Started
- 2024-02
- Registry
- NCT06544083
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingStereotactic Body Radiation Therapy for the Safety and Prognosis of Small Intrahepatic Recurrent HCC
- Phase
- N/A
- Started
- 2023-05
- Registry
- NCT05596630
Age 18 years to 80 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingRaman Spectroscopy-Based Deep Learning Model for Early Pan-Cancer Early Diagnosis
- Phase
- Not given
- Started
- 2022-09
- Registry
- NCT06822413
Age not stated (registered criteria)
Led by Second Affiliated Hospital, Zhejiang University; 3 listed hospitals as study sitesHangzhou, Nanchang, Shanghai
- RecruitingRFA Plus Carrizumab vs Carrizumab Alone for HCC
- Phase
- Phase 2
- Started
- 2020-08
- Registry
- NCT04150744
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- Not yet recruitingExploration of Sintilimab + Bevacizumab + AG Chemotherapy as First-Line Treatment for Unresectable Advanced/Metastatic Cholangiocarcinoma
- Phase
- Phase 2
- Started
- 2026-01
- Registry
- NCT07328802
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- Not yet recruitingAdjuvant Stereotactic Body Radiotherapy (SBRT) for Hepatocellular Carcinoma After Hepatectomy With Narrow Margin: a Prospective, Multi-center, Randomized Controlled, Open-labelled, Phase III Study
- Phase
- N/A
- Started
- 2023-03
- Registry
- NCT05602974
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
- Phase
- Phase 2
- Started
- 2025-06
- Registry
- NCT07327034
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 39 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Ganzhou, Guangzhou, Guilin, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shenyang, Tianjin, Wuhan, Xi'an, Xuzhou, Yinchuan, Zhengzhou
- RecruitingCT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical Resection
- Phase
- Phase 1
- Started
- 2023-10
- Registry
- NCT06560827
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Shanghai, Shenyang, Tianjin, Wuhan, Zhengzhou
- Not yet recruitingMultimodal Thermal Therapy With Targeted and Immunotherapy for Untreated Unresectable HCC
- Phase
- N/A
- Started
- 2026-10
- Registry
- NCT07596134
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesHangzhou, Nanchang, Taizhou
- Not yet recruiting29-Gene Liver Cancer Subtype and Immunotherapy Effectiveness
- Phase
- Not given
- Started
- 2025-08
- Registry
- NCT07100236
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Hangzhou, Hefei, Shanghai, Wenzhou, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led68
- Quantitative analysis of enhanced CT in predicting microvascular invasion and pathological grading of hepatocellular carcinoma.
- A pH-Sensitive Nanosized Covalent-Organic Polymer for Enhanced Tumor Photodynamic Immunotherapy by Hypoxia Relief and STAT3 Inhibition.
- Lactate drives senescence-resistant lineages in hepatocellular carcinoma via histone H2B lactylation of NDRG1.
- Network meta-analysis of the efficacy and safety of ablation for hepatocellular carcinoma under different imaging guidance.
- Heterogeneity in polyamine metabolism dictates prognosis and immune checkpoint blockade response in hepatocellular carcinoma.
- SPP1 promotes malignant characteristics and drug resistance in hepatocellular carcinoma by activating fatty acid metabolic pathway.
- METTL4 and METTL5 as biomarkers for recurrence-free survival in hepatocellular carcinoma patients.
- Protective Effects of GalNac-Modified Red Blood Cell-Derived Extracellular Vesicles Against Liver Diseases.
- Redox-driven hybrid nanoenzyme dynamically activating ferroptosis and disulfidptosis for hepatocellular carcinoma theranostics.
- A Conserved FABP5high Macrophage Subset Promotes Fibrosis and Carcinogenesis in Advanced Liver Disease.
- Hepatic micropeptide modulates mitochondrial RNA processing machinery in hepatocellular carcinoma.
- A long-term self-driven metronomic photodynamic system for cancer therapy.
- Mendelian randomization and nomogram-based prediction of hepatocellular carcinoma risk in patients with hepatitis B cirrhosis.
- Efficacy and safety of stereotactic body radiotherapy for hepatocellular carcinoma with tumor thrombus in right atrium: a two-center retrospective review.
- Multi-omic analysis reveals elevated BRI3BP expression associated with hepatocellular carcinoma progression and poor prognosis.
- Bicarbonate-integrated transarterial chemoembolization (TACE) in real-world hepatocellular carcinoma.
- Pharmacological mechanisms of carvacrol against hepatocellular carcinoma by network pharmacology and molecular docking.
- RHEB neddylation by the UBE2F-SAG axis enhances mTORC1 activity and aggravates liver tumorigenesis.
- Autophagy inhibitor-sensitized artificially activated neutrophils against hepatocellular carcinoma.
- Modified CEUS LI-RADS With Perfluorobutane in Patients at High-Risk for Hepatocellular Carcinoma: A Systematic Review and Network Meta-Analysis.
- Radiomics-based Machine Learning to Predict the Recurrence of Hepatocellular Carcinoma: A Systematic Review and Meta-analysis.
- Aggregation-induced emission: Application in diagnosis and therapy of hepatocellular carcinoma.
- Poly(lactic acid hydroxyacetic acid)-poly(ethylene glycol)-modified ginsenoside Rg3 nanomedicine enhances anti-tumor effect in hepatocellular carcinoma.
- Subtype-specific human endogenous retrovirus K102 envelope protein is a novel serum immunosuppressive biomarker of cancer.
- Effects of sinomenine on a rat orthotopic liver carcinoma model.
- Transcription Factor E2F1 Enhances Hepatocellular Carcinoma Cell Proliferation and Stemness by Activating GINS1.
- Macrophages as Targets in Hepatocellular Carcinoma Therapy.
- Transcription factor 7 like 2 promotes metastasis in hepatocellular carcinoma via NEDD9-mediated activation of AKT/mTOR signaling pathway.
- A Poly(amino acid)-Based Nanomedicine Strategy: Telomere-Telomerase Axis Targeting and Magnetic Resonance Imaging in Hepatocellular Carcinoma Treatment.
- EphrinB2 drives osteogenic fate of adult cardiac fibroblasts in a calcium influx dependent manner.
- Hepatoid adenocarcinoma-Clinicopathological features and molecular characteristics.
- Anti-PD-1/PD-L1 immunotherapy in conversion treatment of locally advanced hepatocellular carcinoma.
- Impact of radiation therapy and alpha-fetoprotein level on survival outcomes for patients with hepatocellular carcinoma: A population-based study.
- Case Report: Cadonilimab-related toxic epidermal necrolysis-like reactions successfully treated with supplemental Adalimumab.
- 5'-tiRNA-Gln inhibits hepatocellular carcinoma progression by repressing translation through the interaction with eukaryotic initiation factor 4A-I.
- TRPM2 regulates cell cycle through the Ca2+-CaM-CaMKII signaling pathway to promote HCC.
- m6A regulator-mediated methylation modification highlights immune infiltration patterns for predicting risk in hepatocellular carcinoma.
- A negative feedback loop between KLF9 and the EMT program dictates metastasis of hepatocellular carcinoma.
- Evaluation of a Tumor-Targeting Oligosaccharide Nanosystem in BNCT on an Orthotopic Hepatocellular Carcinoma Model.
- Expression and prognostic impact of NTF3 and TrkC in hepatocellular carcinoma.
- Response to Letter to the Editor Regarding the Article "Contrast-Enhanced Ultrasound Liver Imaging Reporting and Data System in Diagnosing Hepatocellular Carcinoma: Diagnostic Performance and Interobserver Agreement" by Zhou and Collaborato
- Identification of Immune-Related Markers in Hepatocellular Carcinoma Based on Gene Co-expression Network.
- Design, synthesis, and biological evaluation of quinazoline derivatives with covalent reversible warheads as potential FGFR4 inhibitors.
- Transfer RNA-derived fragment 5'tRF-Gly promotes the development of hepatocellular carcinoma by direct targeting of carcinoembryonic antigen-related cell adhesion molecule 1.
- The synergistic antitumor effect of IL-6 neutralization with NVP-BEZ235 in hepatocellular carcinoma.
- Genetic dominance of transforming growth factor-β1 polymorphisms in chronic liver disease.
- Implications of m6A-associated snRNAs in the prognosis and immunotherapeutic responses of hepatocellular carcinoma.
- Nanosecond pulsed electric field interrupts the glycogen metabolism in hepatocellular carcinoma by modifying the osteopontin pathway.
- SLPI suppresses hepatocellular carcinoma progression via endoplasmic reticulum stress induced apoptosis.
- Single-cell immune signature for detecting early-stage HCC and early assessing anti-PD-1 immunotherapy efficacy.
- Treatment of microvascular invasion in hepatocellular carcinoma with drug-loaded nanocomposite platform under synergistic effect of magnetic field/near-infrared light.
- The role of AURKA/miR-199b-3p in hepatocellular carcinoma cells.
- Role of m6A RNA methylation in the development of hepatitis B virus-associated hepatocellular carcinoma.
- Ultra-thin layered double hydroxide-mediated photothermal therapy combine with asynchronous blockade of PD-L1 and NR2F6 inhibit hepatocellular carcinoma.
- Alkalization of cellular pH leads to cancer cell death by disrupting autophagy and mitochondrial function.
- Circulating MicroRNA Panel as a Diagnostic Marker for Hepatocellular Carcinoma.
- Contrast-Enhanced Ultrasound Liver Imaging Reporting and Data System in Diagnosing Hepatocellular Carcinoma: Diagnostic Performance and Interobserver Agreement.
- Downregulation of snoRNA SNORA52 and Its Clinical Significance in Hepatocellular Carcinoma.
- Tadalafil enhances the therapeutic efficacy of BET inhibitors in hepatocellular carcinoma through activating Hippo pathway.
- REPLY.
- miR-26b enhances the sensitivity of hepatocellular carcinoma to Doxorubicin via USP9X-dependent degradation of p53 and regulation of autophagy.
- Self-amplification of oxidative stress with tumour microenvironment-activatable iron-doped nanoplatform for targeting hepatocellular carcinoma synergistic cascade therapy and diagnosis.
- RNA N6-Methyladenosine Patterns in Hepatocellular Carcinoma Reveal a Distinct Immune Infiltration Landscape and Clinical Significance.
- CEUS examination of the outcome of radiofrequency ablation of canine prostate lesions.
- linc‑ROR facilitates hepatocellular carcinoma resistance to doxorubicin by regulating TWIST1‑mediated epithelial‑mesenchymal transition.
- Glycolysis-related gene expression profiling serves as a novel prognosis risk predictor for human hepatocellular carcinoma.
- An independent poor-prognosis subtype of hepatocellular carcinoma based on the tumor microenvironment.
- CT radiomics nomogram for the preoperative prediction of severe post-hepatectomy liver failure in patients with huge (≥ 10 cm) hepatocellular carcinoma.
Chinese-language papers (not in the count)3
- [New perspective of diagnosis and treatment of hepatocellular carcinoma complicated with portal vein tumor thrombosis].
- [Progress in surgical treatment of hepatocellular carcinoma with tumor thrombus in the inferior vena cava].
- [The clinical value of terminal branches portal vein embolization for hepatocellular carcinoma with insufficient future liver remnant].
All its trials on ClinicalTrials.gov, any status34
- Exploration of Sintilimab + Bevacizumab + AG Chemotherapy as First-Line Treatment for Unresectable Advanced/Metastatic Cholangiocarcinoma
- A Prospective, Randomized Study of TACE Combined With Sintilimab, Bevacizumab, and Ipilimumab N01 Treating Advanced HCC
- Construction and Clinical Validation of a Predictive Model for Postoperative Adjuvant Therapy in Hepatocellular Carcinoma Based on Whole-Slide Digital Pathological Images and Deep Learning
- Study on the Classification of Comprehensive Treatment Effect of Hepatocellular Carcinoma
- Early-stage Detection of Liver Cancer by Proteins in Peripheral Blood
- Stereotactic Body Radiation Therapy for the Safety and Prognosis of Small Intrahepatic Recurrent HCC
- Adjuvant Stereotactic Body Radiotherapy (SBRT) for Hepatocellular Carcinoma After Hepatectomy With Narrow Margin: a Prospective, Multi-center, Randomized Controlled, Open-labelled, Phase III Study
- Raman Spectroscopy-Based Deep Learning Model for Early Pan-Cancer Early Diagnosis
- RFA Plus Carrizumab vs Carrizumab Alone for HCC
- Single-Arm Clinical Study of Icaritin Soft Capsules as Adjuvant Therapy for Hepatocellular Carcinoma Patients at High Risk of Postoperative Recurrence
- the Effect of Nutrition-optimized Prehabilitation on Perioperative Intervention in Primary Liver Carcinoma
- Clinical Application of Quantitative Major Imaging Features of CEUS LI-RADS
- Triple Recipient Strategy Using Split, Domino, and Auxiliary Techniques
- Preoperative Stereotactic Body Radiotherapy (SBRT) Followed by Hepatectomy for Centrally Located Hepatocellular Carcinoma: a Prospective, Single-center, Phase I Study
- The Synergistic Effect of Portal Venous Supply Control and Immunotherapy in Hepatocellular Carcinoma
- Identification and Prognostic Value of Key Genes in Hepatocellular Carcinoma
- Study of TACE Combined With Lenvatinib to Prevent Postoperative Recurrence in Patients With MVI Positive HCC
- Application Value of CEUS Li-RADS in Hepatic Focal Lesions in Patients With Non-high Risk Factors for HCC
- Comparing SonoVue With Sonazoid Using CEUS-LIRADS in HCC
- Stereotactic Body Radiotherapy and Surgery for Early-stage Hepatocellular Carcinoma
- Study of PolyIC and PD-1 mAb in Subjects With Unresectable Hepatocellular Carcinoma
- Stereotactic Body Radiotherapy and Microwave Ablation for Recurrent Small Hepatocellular Carcinoma
- Superb Micro-vascular Imaging for Evaluation of Hepatic Lesions
- The Efficacy of Hepatectomy or TILA-TACE in Patients With Resectable Hepatocellular Carcinoma
- TILA-TACE in Treatment of Hepatocellular Carcinoma
- Stereotactic Body Radiotherapy Based Treatment for Hepatocellular Carcinoma With Extensive Portal Vein Tumor Thrombosis
- Postoperative TACE(Transhepatic Arterial Chemotherapy And Embolization) for Patients With Hepatocellular Carcinoma
- Multimodal Thermal Therapy With Targeted and Immunotherapy for Untreated Unresectable HCC
- 29-Gene Liver Cancer Subtype and Immunotherapy Effectiveness
- ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
- CT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical Resection
- A Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer With PVTT, HVTT or IVCTT After Initial Ate/Bev
- Huaier Granule for Prevention of Recurrence and Metastasis of Hepatocarcinoma Following Local Ablation
- Hepatocellular Carcinoma Registry in Asia: The INSIGHT Registry
Cancer
Stomach cancer
胃癌Led 58 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.6%.
9 hospitals in Hangzhou for stomach cancer218 hospitals in China for stomach cancer
Open trials with this hospital 13
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingExploratory Study on the Efficacy of Betaine Hydrochloride in Treating Autoimmune Gastritis
- Phase
- N/A
- Started
- 2025-01
- Registry
- NCT06881511
Age 18 years to 80 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingTransarterial Neoadjuvant Chemotherapy vs.Traditional Intravenous Chemotherapy For Locally Advanced Gastric Cancer With SOX+PD-1
- Phase
- Phase 3
- Started
- 2023-03
- Registry
- NCT05593458
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingStudy of Comparing of With and Without Sequential Therapy of S-1
- Phase
- Phase 3
- Started
- 2023-01
- Registry
- NCT05813015
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingThe Relationship Between Scar Formation and ESD Depth in Therapy for Gastric Carcinoma
- Phase
- N/A
- Started
- 2022-01
- Registry
- NCT05323929
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingRaman Spectroscopy-Based Deep Learning Model for Early Pan-Cancer Early Diagnosis
- Phase
- Not given
- Started
- 2022-09
- Registry
- NCT06822413
Age not stated (registered criteria)
Led by Second Affiliated Hospital, Zhejiang University; 3 listed hospitals as study sitesHangzhou, Nanchang, Shanghai
- Not yet recruitingAI-Assisted Novel rbcDNA Detection for Early Gastric Cancer Diagnosis
- Phase
- Not given
- Started
- 2026-09
- Registry
- NCT07782294
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang University; 2 listed hospitals as study sitesAnyang, Hangzhou, Shanghai
- RecruitingClinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
- Phase
- Phase 3
- Started
- 2026-04
- Registry
- NCT07385703
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 62 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Changzhou, Chengde, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Nanchang, Nanchong, Nanjing, Qingdao, Shanghai, Shantou, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xuzhou, Yangzhou, Zhengzhou
- RecruitingRadical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy
- Phase
- Phase 3
- Started
- 2026-12
- Registry
- NCT07789184
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 25 listed hospitals as study sitesBeijing, Changchun, Chongqing, Dalian, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Qingdao, Shanghai, Tianjin, Urumqi, Wuhan, Xi'an
- RecruitingReal-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
- Phase
- Not given
- Started
- 2025-02
- Registry
- NCT06846996
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 31 listed hospitals as study sitesBeijing, Changchun, Fuzhou, Guangzhou, Haikou, Hangzhou, Nanjing, Shanghai, Shantou, Shenyang, Taiyuan, Taizhou, Tianjin, Xuzhou, Zhengzhou
- RecruitingA Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2025-08
- Registry
- NCT07070232
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesChongqing, Hangzhou, Tianjin, Wuhan
- RecruitingA Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors
- Phase
- Phase 1
- Started
- 2023-08
- Registry
- NCT06043466
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHangzhou
- RecruitingA Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2022-01
- Registry
- NCT05150691
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 34 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chongqing, Guangzhou, Hangzhou, Hefei, Jinan, Nanning, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wenzhou, Wuhan, Wuxi, Xi'an, Xiamen, Xuzhou, Yantai, Zhengzhou
- Not yet recruitingPerioperative Chemotherapy Plus Toripalimab for Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma
- Phase
- Phase 2
- Started
- 2023-07
- Registry
- NCT05970627
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesHangzhou, Ningbo
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led58
- AI-Assisted Detection of Early Gastric Cancer via Visualization of Mucosal Acidity Compromise During Endoscopy.
- Postoperative survival evaluation of patients with Siewert II adenocarcinoma of esophagogastric junction: a population-based study.
- Effects of Neoadjuvant Chemotherapy on Early Postoperative Anxiety and Depression in Patients With Gastric Cancer: An Observational Study.
- Helicobacter pylori reversing the landscape of neoadjuvant immunotherapy for microsatellite stable gastric cancer: a multicenter cohort study.
- Artificial Intelligence and Multimodality Data Integration Decipher Tertiary Lymphoid Structure Maturity in Gastric Cancer.
- A real-world study on the characteristics of autoimmune gastritis: A single-center retrospective cohort in China.
- Gastric SMARCA4-deficient undifferentiated tumors: clinicopathological analysis of two cases in a single center.
- Latent Profile Analysis and Influencing Factors of Fear of Progression in Patients after Endoscopic Submucosal Dissection for Early Gastric Cancer.
- Analysis of the risk of metachronous colorectal cancer and long-term prognosis in patients following gastrectomy for gastric cancer.
- CALCR interaction with ANTXR1 drives gastric tumor growth and metastasis via AKT signaling pathway.
- Ephrin A1 functions as a ligand of EGFR to promote EMT and metastasis in gastric cancer.
- DR30318, a novel tri-specific T cell engager for Claudin 18.2 positive cancers immunotherapy.
- Tumor suppressive function of IGF2BP1 in gastric cancer through decreasing MYC.
- Research advances in the molecular classification of gastric cancer.
- Causal link between hypothyroidism and gastric cancer risk: insights gained through multivariable Mendelian randomization and mediation analysis.
- Gastric cancer in pregnancy: a review.
- Refractory Diarrhea and Gastric Adenocarcinoma, Just a Coincidence?
- NOX4 regulates gastric cancer cell invasion and proliferation by increasing ferroptosis sensitivity through regulating ROS.
- Comparison of postoperative survival between early-onset and late-onset adenocarcinoma of esophagogastric junction: a population-based study.
- Unexpected Multiple Gastrointestinal Cancers in a Patient with Chronic Eosinophilia: A Case Report.
- Identification of oxeiptosis-associated lncRNAs and prognosis-related signature to predict the immune status in gastric cancer.
- Correlation of Neuroendocrine Differentiation with a Distinctively Suppressive Immune Microenvironment in Gastric Cancer.
- Two-sample Mendelian randomization analysis of the relationship between periodontitis and risk of upper gastrointestinal cancers.
- Predictive modeling of lower extreme deep vein thrombosis following radical gastrectomy for gastric cancer: based on multiple machine learning methods.
- Influence of Primary Tumor Resection on Survival of Patients With Metastatic Siewert Type II Adenocarcinoma of the Esophagogastric Junction: A Population-Based, Propensity-Matched Analysis.
- Hepatoid adenocarcinoma-Clinicopathological features and molecular characteristics.
- Single-cell characteristics and malignancy regulation of alpha-fetoprotein-producing gastric cancer.
- Efficacy of PD-1 Inhibitors in First-Line Treatment for Advanced Gastroesophageal Junction and Gastric Cancer by Subgroups: A Systematic Review and Meta-Analysis.
- MAPK4 silencing in gastric cancer drives liver metastasis by positive feedback between cancer cells and macrophages.
- A 5-Year Follow-Up of a Submucosal Tumor in the Stomach.
- Single-Cell Profiling of Tumor Immune Microenvironment Reveals Immune Irresponsiveness in Gastric Signet-Ring Cell Carcinoma.
- Gastric microbiota in gastric cancer and precancerous stages: Mechanisms of carcinogenesis and clinical value.
- Switch/Sucrose Non-Fermentable Complex-Deficient Rhabdoid Carcinoma of Stomach: A Rare Case Report and Literature Review.
- Diabetes Mellitus and Gastric Cancer: Correlation and Potential Mechanisms.
- Iatrogenic metastasis of gastric adenocarcinoma to the abdomen.
- Depletion of C12orf48 inhibits gastric cancer growth and metastasis via up-regulating Poly r(C)-Binding Protein (PCBP) 1.
- Effects of different pepsinogen cut offs in the screening of apparently healthy people.
- Computed tomography in the size measurement of gastric gastrointestinal stromal tumors: Implication to risk stratification and "wait-and-see" tactics.
- A rare gastric lesion: diminutive, well-differentiated, Grade 3, type 3 gastric neuroendocrine tumor with extremely high ki-67 index removed en bloc under endoscopy.
- Adverse effects of low serum lipoprotein cholesterol on the immune microenvironment in gastric cancer: a case‒control study.
- HER2 protein expression correlates with Lauren classification and P53 in gastric cancer patients.
- HOXC10 indicates poor survival outcome in gastric cancer and promotes G1/S cell cycle transition through transcriptional repression of p21.
- DeepTI: A deep learning-based framework decoding tumor-immune interactions for precision immunotherapy in oncology.
- Gastric Metastasis After Tibial Sarcoma Surgery.
- Serum pepsinogen levels in different regions of China and its influencing factors: a multicenter cross-sectional study.
- Identification of the angiogenesis related genes for predicting prognosis of patients with gastric cancer.
- Predictors of Lymph Node Metastasis in Siewert Type II T1 Adenocarcinoma of the Esophagogastric Junction: A Population-Based Study.
- Relationship Between Postoperative Complications and the Prognosis of Gastric Carcinoma Patients Who Underwent Surgical Resection: A Systematic Review and Meta-Analysis.
- A clinical model to predict distant metastasis in patients with superficial gastric cancer with negative lymph node metastasis and a survival analysis for patients with metastasis.
- Gastric mucin phenotype indicates aggressive biological behaviour in early differentiated gastric adenocarcinomas following endoscopic treatment.
- Dynamics of Endocytosis and Degradation of Antibody-Drug Conjugate T-DM1 in HER2 Positive Cancer Cells.
- Current and potential biomarkers in gastric cancer: a critical review of the literature.
- A commentary on "Efficacy and safety of short-term (3 days) enoxaparin in preventing venous thromboembolism after gastric cancer surgery: A single-center, prospective cohort study" (Int J Surg 2021; 89:105946).
- "Sweet tooth"-oriented SN38 prodrug delivery nanoplatform for targeted gastric cancer therapy.
- Heterogeneity of MSI-H gastric cancer identifies a subtype with worse survival.
- Prodrug polymeric micelles integrating cancer-associated fibroblasts deactivation and synergistic chemotherapy for gastric cancer.
- Immunotherapies for well-differentiated grade 3 gastroenteropancreatic neuroendocrine tumors: A new category in the World Health Organization classification.
- Decreased exosome-delivered miR-486-5p is responsible for the peritoneal metastasis of gastric cancer cells by promoting EMT progress.
All its trials on ClinicalTrials.gov, any status36
- AI-Assisted Novel rbcDNA Detection for Early Gastric Cancer Diagnosis
- Exploratory Study on the Efficacy of Betaine Hydrochloride in Treating Autoimmune Gastritis
- The Relationship Between Scar Formation and ESD Depth in Therapy for Gastric Carcinoma
- Raman Spectroscopy-Based Deep Learning Model for Early Pan-Cancer Early Diagnosis
- Electroacupuncture Combined With Paclitaxel Protein-bound and PD-1 Antibody for Second-line Treatment of HER2 Negative, pMMR/MSS Advanced Gastric Cancer
- taVNS Reduces Postoperative Pain and Complications in Patients With Gastric and Intestinal Tumors
- Metabonomics Study of Chronic Gastritis and Gastric Carcinoma
- Nutrition Education Program for Postoperative Patients With Gastric Cancer
- Intra-arterial Infusion Chemotherapy Combined With Sodium Bicarbonate for Unresectable Gastric Cancer
- The Research of Constructing a Risk Assessment Model for Gastric Cancer Based on Machine Learning
- Nasal Endoscopic Screening and Risk Assessment for Early Gastric Cancer
- Transarterial Neoadjuvant Chemotherapy vs.Traditional Intravenous Chemotherapy For Locally Advanced Gastric Cancer With SOX+PD-1
- Study of Comparing of With and Without Sequential Therapy of S-1
- Evaluation of Consistency of PDX Model for Predicting Therapeutic Effect of Gastric Cancer
- Study of Tislelizumab in Combination With SOX for the Treatment of Gastric Cancer With Liver Metastases
- Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy
- Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
- A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
- Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
- Perioperative Chemotherapy Plus Toripalimab for Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma
- A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors
- A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
- Research on Intelligent Screening and Decision-making for Neoadjuvant Therapy in Locally Advanced Gastric Cancer Based on Multi-omics Integration
- Real-World Observational Study to Describe Treatment Patterns in Patients With HER2-Positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer in East Asia
- Perioperative Chemotherapy Plus Trastuzumab Plus Toripalimab in HER2 Positive Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma
- Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
- Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.
- PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer
- Study of ESG401 in Adults With Solid Tumors
- Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs
- A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression
- A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers
- Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer
- A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer
- Chemotherapy Alone Versus Surgery Plus Chemotherapy for Distal Gastric Cancer With One Non-curable Factor
- Extensive Intraoperative Peritoneal Lavage After Curative Gastrectomy for Locally Advanced Gastric Cancer (SEIPLUS)
Cancer
Retinoblastoma
视网膜母细胞瘤Led 1 of the 301 English-language PubMed papers on retinoblastoma with an author in mainland China, 2021–2025: 0.3%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
5 hospitals in Hangzhou for retinoblastoma196 hospitals in China for retinoblastoma
No open trial on retinoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Earlier papers (2016–2020)1
Cancer
Chordoma
脊索瘤Led no English-language PubMed papers on chordoma in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
1 hospital in Hangzhou for chordoma88 hospitals in China for chordoma
No open trial on chordoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Earlier papers (2016–2020)1
Cancer
Osteosarcoma
骨肉瘤Led 16 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.7%.
- Open trials led
- 0
- recruiting or about to
22 hospitals in Hangzhou for osteosarcoma742 hospitals in China for osteosarcoma
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas
- Phase
- Phase 2
- Started
- 2023-06
- Registry
- NCT05830123
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesBeijing, Changsha, Guangzhou, Hangzhou, Shanghai, Tianjin, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led16
- Soluble immune checkpoint factors reveal high-risk osteosarcoma subtypes and enable early metastasis prediction.
- Immune-related glycosylation genes based classification predicts prognosis and therapy options of osteosarcoma.
- HSP47 inhibition-induced CD155 expression through TRAF2 deubiquitination promotes tumor immune evasion.
- PSMD14 is a novel prognostic marker and therapeutic target in osteosarcoma.
- Investigating the synergy of Shikonin and Valproic acid in inducing apoptosis of osteosarcoma cells via ROS-mediated EGR1 expression.
- Small Nuclear Ribonucleoprotein Polypeptides B and B1 Promote Osteosarcoma Progression via Activating the Ataxia-Telangiectasia Mutated Signaling Pathway through Ribonucleotide Reductase Subunit M2.
- Human γδ T cells induce CD8+ T cell antitumor responses via antigen-presenting effect through HSP90-MyD88-mediated activation of JNK.
- Cancer cells reprogram to metastatic state through the acquisition of platelet mitochondria.
- Chitosan oligosaccharide suppresses osteosarcoma malignancy by inhibiting CEMIP via the PI3K/AKT/mTOR pathway.
- Mitochondria-Targeting Polymer Micelle of Dichloroacetate Induced Pyroptosis to Enhance Osteosarcoma Immunotherapy.
- Metabolic control of CD47 expression through LAT2-mediated amino acid uptake promotes tumor immune evasion.
- MerTK-mediated efferocytosis promotes immune tolerance and tumor progression in osteosarcoma through enhancing M2 polarization and PD-L1 expression.
- Transcription factor ELK1 accelerates aerobic glycolysis to enhance osteosarcoma chemoresistance through miR-134/PTBP1 signaling cascade.
- Cell Differentiation Trajectory-Associated Molecular Classification of Osteosarcoma.
- Exploration of Immune-Related Gene Expression in Osteosarcoma and Association With Outcomes.
- A panel of eight mRNA signatures improves prognosis prediction of osteosarcoma patients.
Earlier papers (2016–2020)36
- 2-methylbenzoyl berbamine, a multi-targeted inhibitor, suppresses the growth of human osteosarcoma through disabling NF-κB, ERK and AKT signaling networks.
- Water extract of sporoderm-broken spores of Ganoderma lucidum enhanced pd-l1 antibody efficiency through downregulation and relieved complications of pd-l1 monoclonal antibody.
- TFAP2C-mediated LINC00922 signaling underpins doxorubicin-resistant osteosarcoma.
- The multiple function of long noncoding RNAs in osteosarcoma progression, drug resistance and prognosis.
- A Delta-radiomics model for preoperative evaluation of Neoadjuvant chemotherapy response in high-grade osteosarcoma.
- Andrographolide induces apoptosis in human osteosarcoma cells via the ROS/JNK pathway.
- Estrogen receptor β induces autophagy of osteosarcoma through the mTOR signaling pathway.
- Autophagy inhibitor enhance ZnPc/BSA nanoparticle induced photodynamic therapy by suppressing PD-L1 expression in osteosarcoma immunotherapy.
- Innate Immune Cells: A Potential and Promising Cell Population for Treating Osteosarcoma.
- Inflammatory responses and biological characteristics of human osteosarcoma cells and umbilical cord blood mononuclear cells in co-cultured microenvironment.
- Anti-CD166/4-1BB chimeric antigen receptor T cell therapy for the treatment of osteosarcoma.
- Functional Genetic Single-Nucleotide Polymorphisms (SNPs) in Cyclin-Dependent Kinase Inhibitor 2A/B (CDKN2A/B) Locus Are Associated with Risk and Prognosis of Osteosarcoma in Chinese Populations.
- Molecular mechanisms of estrogen receptor β-induced apoptosis and autophagy in tumors: implication for treating osteosarcoma.
- Epigenetic Regulation of CXCL12 Plays a Critical Role in Mediating Tumor Progression and the Immune Response In Osteosarcoma.
- PARK2 inhibits osteosarcoma cell growth through the JAK2/STAT3/VEGF signaling pathway.
- MicroRNA-330-3p Expression Indicates Good Prognosis and Suppresses Cell Proliferation by Targeting Bmi-1 in Osteosarcoma.
- Survival Prediction in High-grade Osteosarcoma Using Radiomics of Diagnostic Computed Tomography.
- Decitabine Enhances Vγ9Vδ2 T Cell-Mediated Cytotoxic Effects on Osteosarcoma Cells via the NKG2DL-NKG2D Axis.
- Valproic Acid Combined with Zoledronate Enhance γδ T Cell-Mediated Cytotoxicity against Osteosarcoma Cells via the Accumulation of Mevalonate Pathway Intermediates.
- Melatonin inhibits osteosarcoma stem cells by suppressing SOX9-mediated signaling.
- Clinical Features and Prognostic Factors in Elderly Ewing Sarcoma Patients.
- Cantharidin Inhibits Anti-Apoptotic Bcl-2 Family Proteins and Induces Apoptosis in Human Osteosarcoma Cell Lines MG-63 and MNNG/HOS via Mitochondria-Dependent Pathway.
- Meta-analysis of serum lactate dehydrogenase and prognosis for osteosarcoma.
- Paeoniflorin induces G2/M cell cycle arrest and caspase-dependent apoptosis through the upregulation of Bcl-2 X-associated protein and downregulation of B-cell lymphoma 2 in human osteosarcoma cells.
- Zinc phthalocyanine encapsulated in polymer micelles as a potent photosensitizer for the photodynamic therapy of osteosarcoma.
- Combination therapy with L-arginine and α-PD-L1 antibody boosts immune response against osteosarcoma in immunocompetent mice.
- Escin induces caspase-dependent apoptosis and autophagy through the ROS/p38 MAPK signalling pathway in human osteosarcoma cells in vitro and in vivo.
- Endostar combined with chemotherapy in a pediatric osteosarcoma with pulmonary metastasis and malignant pleural effusion: A case report.
- Three hematological indexes that may serve as prognostic indicators in patients with primary, high-grade, appendicular osteosarcoma.
- A review and outlook in the treatment of osteosarcoma and other deep tumors with photodynamic therapy: from basic to deep.
- Overendocytosis of superparamagnetic iron oxide particles increases apoptosis and triggers autophagic cell death in human osteosarcoma cell under a spinning magnetic field.
- Bio-inspired cisplatin nanocarriers for osteosarcoma treatment.
- MicroRNA-133a Inhibits Osteosarcoma Cells Proliferation and Invasion via Targeting IGF-1R.
- The role of CTLA-4 and PD-1 in anti-tumor immune response and their potential efficacy against osteosarcoma.
- Sinomenine prevents metastasis of human osteosarcoma cells via S phase arrest and suppression of tumor-related neovascularization and osteolysis through the CXCR4-STAT3 pathway.
- SIRT1 promotes metastasis of human osteosarcoma cells.
All its trials on ClinicalTrials.gov, any status6
- A Clinical Study of Surufatinib Combined With Chemotherapy as Neoadjuvant Treatment in Osteosarcoma
- A Study of Sulfatinib on Relapsed or Refractory Drug Resistant Osteosarcoma
- Evaluation of Myocardial Injury After Anthracycline Chemotherapy in Osteosarcoma Patients Using CMR
- Proteomics Research of Osteosarcoma
- Zoledronic Acid in Decrease the Lung Metastatic Rate of Osteosarcoma
- ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas
Cancer
Gastrointestinal stromal tumour
胃肠道间质瘤Led 4 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 0.8%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
16 hospitals in Hangzhou for gastrointestinal stromal tumour261 hospitals in China for gastrointestinal stromal tumour
No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led4
- A CT-based nomogram established for differentiating gastrointestinal heterotopic pancreas from gastrointestinal stromal tumor: compared with a machine-learning model.
- Duodenal neuroendocrine neoplasms on enhanced CT: establishing a diagnostic model with duodenal gastrointestinal stromal tumors in the non-ampullary area and analyzing the value of predicting prognosis.
- Building contrast-enhanced CT-based models for preoperatively predicting malignant potential and Ki67 expression of small intestine gastrointestinal stromal tumors (GISTs).
- Computed tomography in the size measurement of gastric gastrointestinal stromal tumors: Implication to risk stratification and "wait-and-see" tactics.
Earlier papers (2016–2020)7
- MicroRNA-30a targets BECLIN-1 to inactivate autophagy and sensitizes gastrointestinal stromal tumor cells to imatinib.
- Endoscopic or laparoscopic resection for small gastrointestinal stromal tumors: a cumulative meta-analysis.
- Diffuse primary extra-gastrointestinal stromal tumor of the peritoneum: A rare case report.
- Prevalence, diagnosis, and treatment of primary hepatic gastrointestinal stromal tumors.
- Resection of GIST in the duodenum and proximal jejunum: A retrospective analysis of outcomes.
- Mesenteric fibromatosis after resection for gastrointestinal stromal tumor of stomach: A case report.
- [A case of neurofibromatosis complicated with small bowel obstruction].
Cancer
Neuroblastoma
神经母细胞瘤Led 3 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.3%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
8 hospitals in Hangzhou for neuroblastoma352 hospitals in China for neuroblastoma
No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led3
- Fibroblast growth factor-21 alleviates proteasome injury via activation of autophagy flux in Parkinson's disease.
- Discovery of Novel Oxazepine Derivatives as Akt/ROCK Inhibitors for Growth Arrest and Differentiation Induction in Neuroblastoma Treatment.
- Dexmedetomidine pretreatment alleviates ropivacaine-induced neurotoxicity via the miR-10b-5p/BDNF axis.
Earlier papers (2016–2020)1
Cancer
Ewing sarcoma
尤文肉瘤Led no English-language PubMed papers on Ewing sarcoma in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
6 hospitals in Hangzhou for Ewing sarcoma139 hospitals in China for Ewing sarcoma
No open trial on Ewing sarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Earlier papers (2016–2020)1
All its trials on ClinicalTrials.gov, any status1
Blood disorders
Multiple myeloma
多发性骨髓瘤Led 5 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.3%.
9 hospitals in Hangzhou for multiple myeloma178 hospitals in China for multiple myeloma
Open trials with this hospital 5
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingNovel CD19/BCMA Dual-Targeted CAR-T Cell Therapy for the Treatment of Relapsed/Refractory Multiple Myeloma
- Phase
- N/A
- Started
- 2025-11
- Registry
- NCT07359014
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingIxazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma
- Phase
- Phase 4
- Started
- 2022-07
- Registry
- NCT05722405
Age 18 years to 80 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingTo Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma
- Phase
- Phase 1/Phase 2
- Started
- 2026-04
- Registry
- NCT07454187
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesHangzhou, Suzhou, Xi'an, Zhengzhou
- RecruitingA Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients
- Phase
- Phase 3
- Started
- 2024-06
- Registry
- NCT06508983
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou, Suzhou, Tianjin, Wuhan, Xi'an, Zhengzhou
- RecruitingA Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- Phase
- Phase 3
- Started
- 2022-10
- Registry
- NCT05552222
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shenzhen, Tianjin, Wenzhou, Wuhan, Xi'an, Xiamen, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led5
- CD27-Armored BCMA CAR T-cell Therapy (CBG-002) for Relapsed and Refractory Multiple Myeloma: A Phase I Clinical Trial.
- Using protein turnover assay to explore the drug mechanism of Carfilzomib.
- Global, regional, and national burden and quality of care of multiple myeloma, 1990-2019.
- New diagnostic strategy for multiple myeloma: A review.
- (-)-Epigallocatechin-3-gallate plays an antagonistic role in the antitumor effect of bortezomib in myeloma cells via activating Wnt/β-catenin signaling pathway.
All its trials on ClinicalTrials.gov, any status10
- Novel CD19/BCMA Dual-Targeted CAR-T Cell Therapy for the Treatment of Relapsed/Refractory Multiple Myeloma
- Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma
- Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma
- To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma
- A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients
- A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
- A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)
- SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies
- APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple Myeloma
Blood disorders
Haemophagocytic lymphohistiocytosis
噬血细胞性淋巴组织细胞增生症Led 2 of the 399 English-language PubMed papers on haemophagocytic lymphohistiocytosis with an author in mainland China, 2021–2025: 0.5%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
4 hospitals in Hangzhou for haemophagocytic lymphohistiocytosis66 hospitals in China for haemophagocytic lymphohistiocytosis
No open trial on haemophagocytic lymphohistiocytosis lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
Blood disorders
Thrombotic thrombocytopenic purpura
血栓性血小板减少性紫癜Led 1 of the 64 English-language PubMed papers on thrombotic thrombocytopenic purpura with an author in mainland China, 2021–2025: 1.6%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
5 hospitals in Hangzhou for thrombotic thrombocytopenic purpura59 hospitals in China for thrombotic thrombocytopenic purpura
No open trial on thrombotic thrombocytopenic purpura lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Earlier papers (2016–2020)1
Other diseases
Neuromyelitis optica spectrum disorder
视神经脊髓炎谱系疾病Led 7 of the 485 English-language PubMed papers on neuromyelitis optica spectrum disorder with an author in mainland China, 2021–2025: 1.4%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
3 hospitals in Hangzhou for neuromyelitis optica spectrum disorder67 hospitals in China for neuromyelitis optica spectrum disorder
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)
- Phase
- Phase 2/Phase 3
- Started
- 2024-07
- Registry
- NCT06413654
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xiamen, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led7
- Aquaporin 4 antibody-positive neuromyelitis optica spectrum disorder with cholangiocarcinoma: Casual or causal association?
- Seizures and epilepsy in multiple sclerosis, aquaporin 4 antibody-positive neuromyelitis optica spectrum disorder, and myelin oligodendrocyte glycoprotein antibody-associated disease.
- Case Report: Neuromyelitis Optica Spectrum Disorder With Progressive Elevation of Cerebrospinal Fluid Cell Count and Protein Level Mimicking Infectious Meningomyelitis: A Diagnostic Challenge.
- Late-onset neuromyelitis optica spectrum disorder mimicking stroke in an elderly Chinese man: Case report.
- Neuromyelitis optica spectrum disorder complicated with Sjögren's syndrome: first pediatric case responsive to mycophenolate mofetil treatment.
- Common genetic variants in PRRC2A are associated with both neuromyelitis optica spectrum disorder and multiple sclerosis in Han Chinese population.
- Evaluation of brain and spinal cord lesion distribution criteria at disease onset in distinguishing NMOSD from MS and MOG antibody-associated disorder.
All its trials on ClinicalTrials.gov, any status2
More papers found outside PubMed (not counted)2
Other diseases
Myasthenia gravis
重症肌无力Led 4 of the 499 English-language PubMed papers on myasthenia gravis with an author in mainland China, 2021–2025: 0.8%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
6 hospitals in Hangzhou for myasthenia gravis93 hospitals in China for myasthenia gravis
No open trial on myasthenia gravis lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Papers it led4
- Normotensive primary aldosteronism in a patient with myasthenia gravis: a localization diagnostic conundrum unraveled by 68Ga-pentixafor PET/CT - a case report with review of literature.
- Contrast-enhanced CT-based radiomics differentiate anterior mediastinum lymphoma from thymoma without myasthenia gravis and calcification.
- Erythroderma in a Patient With Thymoma-Associated Myasthenia Gravis.
- Dynamic changes of peripheral inflammatory markers link with disease severity and predict short-term poor outcome of myasthenia gravis.
Other diseases
Moyamoya disease
烟雾病Led 12 of the 356 English-language PubMed papers on moyamoya disease with an author in mainland China, 2021–2025: 3.4%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
1 hospital in Hangzhou for moyamoya disease47 hospitals in China for moyamoya disease
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingDevelopment and Validation of Risk Prediction Models for Stroke and Cognitive Impairment in Moyamoya Disease and Moyamoya Syndrome
- Phase
- Not given
- Started
- 2026-08
- Registry
- NCT07894107
Age 12 years to 70 years (registered criteria)
Led by Beijing Tiantan Hospital; 12 listed hospitals as study sitesBeijing, Chengdu, Hangzhou, Nanchang, Shanghai, Suzhou, Wuhan, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led12
- Unraveling the links between intracranial artery stenosis, cerebral perfusion, and white matter hyperintensity in moyamoya disease.
- Glymphatic dysfunction in moyamoya disease: The influence of arterial stenosis and ventricular enlargement.
- White matter hyperintensities in cholinergic pathways correlates of cognitive impairment in moyamoya disease.
- Glymphatic System Impairment in the Advanced Stage of Moyamoya Disease.
- Exploring the Impact of Hemoglobin on Cerebral Blood Flow in Arterial Territories and Surgical Outcomes: Potential Implications for Moyamoya Disease Treatment.
- The effects of anastomoses between anterior and posterior circulation on postoperative prognosis of patients with moyamoya disease.
- Altered neurovascular coupling and structure-function coupling in Moyamoya disease affect postoperative collateral formation.
- Hemodynamic Effects of Tortuosity and Stenosis in Superficial Temporal Artery-Middle Cerebral Artery Bypass for Moyamoya Disease.
- Efficacy assessment of superficial temporal artery-middle cerebral artery bypass surgery in treating moyamoya disease from a hemodynamic perspective: a pilot study using computational modeling and perfusion imaging.
- Preoperative Brain Functional Connectivity Improve Predictive Accuracy of Outcomes After Revascularization in Moyamoya Disease.
- Abnormal brain functional and structural connectivity between the left supplementary motor area and inferior frontal gyrus in moyamoya disease.
- Comparison of Operative and Conservative Treatment for Asymptomatic Moyamoya Disease: Preliminary Experience in Small Retrospective Series.
All its trials on ClinicalTrials.gov, any status1
Other diseases
Wilson disease
肝豆状核变性(Wilson 病)Led 8 of the 201 English-language PubMed papers on Wilson disease with an author in mainland China, 2021–2025: 4.0%.
3 hospitals in Hangzhou for Wilson disease28 hospitals in China for Wilson disease
Open trials with this hospital 3
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingRole for Biochemical Assays and Kayser-Fleischer Rings in Diagnosis of Wilson Disease
- Phase
- Not given
- Started
- 2004-01
- Registry
- NCT04965545
Age 6 years to 65 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingClinical Features and Outcome in Patients With Osseomuscular Type of Wilson's Disease
- Phase
- Not given
- Started
- 2004-01
- Registry
- NCT04965558
Age 6 years to 65 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingTrientine Tetrahydrochloride Administered Once a Day for the First Line Treatment of Wilson's Disease Patients.
- Phase
- Phase 3
- Started
- 2026-09
- Registry
- NCT07465718
Age 8 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Hangzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led8
- Neuroimaging correlates of genetics in patients with Wilson's disease.
- Structures of the human Wilson disease copper transporter ATP7B.
- Pathogenicity of Intronic and Synonymous Variants of ATP7B in Wilson Disease.
- Emerging neurological symptoms after liver transplantation: A 6-year follow-up of an adolescent patient with Wilson's disease.
- Serum Neurofilament Light Chain in Wilson's Disease: A Promising Indicator but Unparallel to Real-Time Treatment Response.
- Role for Biochemical Assays and Kayser-Fleischer Rings in Diagnosis of Wilson's Disease.
- Prevalent Pathogenic Variants of ATP7B in Chinese Patients with Wilson's Disease: Geographical Distribution and Founder Effect.
- Challenges and suggestions for precise diagnosis and treatment of Wilson's disease.
All its trials on ClinicalTrials.gov, any status5
- Clinical Features and Outcome in Patients With Osseomuscular Type of Wilson's Disease
- Role for Biochemical Assays and Kayser-Fleischer Rings in Diagnosis of Wilson Disease
- The Individual Therapy for Patients With Wilson's Disease
- Clinical Features and Outcome of Wilson's Disease With Generalized Epilepsy in Chinese Patients
- Trientine Tetrahydrochloride Administered Once a Day for the First Line Treatment of Wilson's Disease Patients.
Other diseases
Anti-NMDA receptor encephalitis
抗 NMDA 受体脑炎Led 4 of the 264 English-language PubMed papers on anti-NMDA receptor encephalitis with an author in mainland China, 2021–2025: 1.5%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
6 hospitals in Hangzhou for anti-NMDA receptor encephalitis126 hospitals in China for anti-NMDA receptor encephalitis
No open trial on anti-NMDA receptor encephalitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led4
- Myelin oligodendrocyte glycoprotein antibody and N-methyl-d-aspartate receptor antibody overlapping syndrome: insights from the recent case reports.
- Case report: Isolated brainstem-cerebellar symptoms in a patient with anti-NMDA receptor encephalitis.
- Inflammatory markers of hemogram parameters as predictive factors for disease severity in anti-N-methyl-D-aspartate receptor encephalitis.
- Seasonal variation in autoimmune encephalitis: A multi-center retrospective study.
Earlier papers (2016–2020)1
Other diseases
Takayasu arteritis
大动脉炎Led no English-language PubMed papers on Takayasu arteritis in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
3 hospitals in Hangzhou for Takayasu arteritis108 hospitals in China for Takayasu arteritis
No open trial on Takayasu arteritis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
Idiopathic pulmonary fibrosis
特发性肺纤维化Led 4 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.4%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
9 hospitals in Hangzhou for idiopathic pulmonary fibrosis333 hospitals in China for idiopathic pulmonary fibrosis
No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led4
- PINK1 deficiency alleviates bleomycin-induced pulmonary fibrosis in mice.
- An Overview of the Role of Genetic factors in Idiopathic Pulmonary Fibrosis: Insights from Epidemiology to Prognosis.
- Identification of key genes associated with idiopathic pulmonary fibrosis and sarcopenia by bioinformatics analysis.
- SPP1 induces idiopathic pulmonary fibrosis and NSCLC progression via the PI3K/Akt/mTOR pathway.
All its trials on ClinicalTrials.gov, any status3
- A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
- A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)
- Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
Other diseases
Amyotrophic lateral sclerosis
肌萎缩侧索硬化症Led 6 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 0.8%.
- Open trials led
- 0
- recruiting or about to
11 hospitals in Hangzhou for amyotrophic lateral sclerosis194 hospitals in China for amyotrophic lateral sclerosis
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RAG-17 in Subjects With Amyotrophic Lateral Sclerosis (ALS) With Superoxide Dismutase Type 1 (SOD1) Gene Mutation
- Phase
- Phase 1
- Started
- 2024-12
- Registry
- NCT06556394
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Chengdu, Hangzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led6
- Clinical characterization and founder effect analysis in Chinese amyotrophic lateral sclerosis patients with SOD1 common variants.
- FUS reads histone H3K36me3 to regulate alternative polyadenylation.
- Clinical feature difference between juvenile amyotrophic lateral sclerosis with SPTLC1 and FUS mutations.
- Pathogenicity classification of SOD1 variants of uncertain significance by in vitro aggregation propensity.
- Taste loss as the sole presenting symptom in Chinese patient with facial onset sensory and motor neuronopathy.
- Aberrant Stress Granule Dynamics and Aggrephagy in ALS Pathogenesis.
Earlier papers (2016–2020)2
All its trials on ClinicalTrials.gov, any status4
- Explore Neuroprotective Effect of Lipoic Acid in Amyotrophic Lateral Sclerosis
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RAG-17 in Subjects With Amyotrophic Lateral Sclerosis (ALS) With Superoxide Dismutase Type 1 (SOD1) Gene Mutation
- A Phase Ⅰ/Ⅱa Study of SNUG01 in Adult Subjects With ALS
- An IIT Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of a Single Intrathecal Injection of SNUG01 in Patients with Amyotrophic Lateral Sclerosis
Other diseases
Fabry disease
法布雷病Led no English-language PubMed papers on Fabry disease in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
7 hospitals in Hangzhou for Fabry disease85 hospitals in China for Fabry disease
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry Disease
- Phase
- Not given
- Started
- 2025-11
- Registry
- NCT07187440
Age 7 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Hangzhou, Harbin, Hefei, Nanjing, Shantou, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Xi'an
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
Other diseases
Pompe disease
庞贝病Led no English-language PubMed papers on Pompe disease in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
2 hospitals in Hangzhou for Pompe disease30 hospitals in China for Pompe disease
No open trial on Pompe disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Chinese-language papers (not in the count)1
Other diseases
Duchenne muscular dystrophy
杜氏肌营养不良Led 1 of the 213 English-language PubMed papers on Duchenne muscular dystrophy with an author in mainland China, 2021–2025: 0.5%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
7 hospitals in Hangzhou for Duchenne muscular dystrophy116 hospitals in China for Duchenne muscular dystrophy
No open trial on Duchenne muscular dystrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
Behçet disease
白塞病Led no English-language PubMed papers on Behçet disease in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
7 hospitals in Hangzhou for Behçet disease149 hospitals in China for Behçet disease
No open trial on Behçet disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
Other diseases
Alport syndrome
Alport 综合征Led 1 of the 58 English-language PubMed papers on Alport syndrome with an author in mainland China, 2021–2025: 1.7%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
4 hospitals in Hangzhou for Alport syndrome60 hospitals in China for Alport syndrome
No open trial on Alport syndrome lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
IgA nephropathy
IgA 肾病Led 2 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.3%.
- Open trials led
- 0
- recruiting or about to
15 hospitals in Hangzhou for IgA nephropathy346 hospitals in China for IgA nephropathy
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
- Phase
- Phase 3
- Started
- 2025-07
- Registry
- NCT06963827
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBaotou, Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Nantong, Ningbo, Shanghai, Shenzhen, Wuxi, Xiamen, Zhuhai
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led2
All its trials on ClinicalTrials.gov, any status2
Other diseases
Osteogenesis imperfecta
成骨不全症Led no English-language PubMed papers on osteogenesis imperfecta in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
2 hospitals in Hangzhou for osteogenesis imperfecta59 hospitals in China for osteogenesis imperfecta
No open trial on osteogenesis imperfecta lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
Congenital diaphragmatic hernia
先天性膈疝Led 1 of the 60 English-language PubMed papers on congenital diaphragmatic hernia with an author in mainland China, 2021–2025: 1.7%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
3 hospitals in Hangzhou for congenital diaphragmatic hernia46 hospitals in China for congenital diaphragmatic hernia
No open trial on congenital diaphragmatic hernia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
Hirschsprung disease
先天性巨结肠Led 1 of the 161 English-language PubMed papers on Hirschsprung disease with an author in mainland China, 2021–2025: 0.6%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
3 hospitals in Hangzhou for Hirschsprung disease82 hospitals in China for Hirschsprung disease
No open trial on Hirschsprung disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
Hereditary angioedema
遗传性血管性水肿Led 1 of the 32 English-language PubMed papers on hereditary angioedema with an author in mainland China, 2021–2025: 3.1%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
1 hospital in Hangzhou for hereditary angioedema30 hospitals in China for hereditary angioedema
No open trial on hereditary angioedema lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Chinese-language papers (not in the count)1
All its trials on ClinicalTrials.gov, any status1
Other diseases
Familial adenomatous polyposis
家族性腺瘤性息肉病Led 4 of the 59 English-language PubMed papers on familial adenomatous polyposis with an author in mainland China, 2021–2025: 6.8%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
4 hospitals in Hangzhou for familial adenomatous polyposis76 hospitals in China for familial adenomatous polyposis
No open trial on familial adenomatous polyposis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led4
- Global burden and trends of the Entamoeba infection-associated diseases from 1990 to 2019: An observational trend study.
- De novo familial adenomatous polyposis associated thyroid cancer with a c.2929delG frameshift deletion mutation in APC: a case report and literature review.
- Role of a Rare Variant in APC Gene Promoter 1B Region in Classic Familial Adenomatous Polyposis.
- Percutaneous ultrasound-guided radiofrequency ablation for giant desmoid tumors of the intra-abdominal cavity in a patient with Gardner syndrome.
Other diseases
Leber hereditary optic neuropathy
Leber 遗传性视神经病变Led no English-language PubMed papers on Leber hereditary optic neuropathy in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
5 hospitals in Hangzhou for Leber hereditary optic neuropathy32 hospitals in China for Leber hereditary optic neuropathy
No open trial on Leber hereditary optic neuropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other linked evidence
Getting in touch
Name card to show staff or a driver
浙江大学医学院附属第二医院
Second Affiliated Hospital, Zhejiang University
杭州
Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.
Inquiry letter in English and Chinese
Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.
Records hospitals usually ask for
- A recent summary or letter from the treating doctor
- Pathology report
- Scans (CT, MRI, PET) with their reports, and the images if possible
- Treatments so far, with dates
- Current medicines
What to do next
Where these numbers come from
Papers
English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions
Trials
ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.
Identifiers and other names
ROR
Second Affiliated Hospital of Zhejiang University; Second Affiliated Hospital of Zhejiang University of Medicine; Second Affiliated Hospital Zhejiang University; Second Affiliated Hospital Zhejiang University College of Medicine; Second Affiliated Hospital of Zhejiang University Medical College; SAHZU